[ad_1]
Medical regulators in Europe on Tuesday supported the World Health Organization’s recommendation to update the antigen formulation of Covid-19 vaccines to target one of the currently dominant vaccines. XBB variants before the next fall vaccination campaign.
Relevant WHO advisory groups have suggested that while they await more data, monovalent XBB-containing vaccines may be considered a reasonable option and priority should be given to individuals at high risk of progression to severe disease such as the elderly, according to the WHO. European Center for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA).
The World Health Organization said in May that new formulations should aim to produce antibody responses to XBB.1.5 or XBB.1.16 variants, adding that other formulations or platforms that achieve neutralizing antibody responses against XBB strains could also be considered.
Relevant WHO advisory groups have suggested that while they await more data, monovalent XBB-containing vaccines may be considered a reasonable option and priority should be given to individuals at high risk of progression to severe disease such as the elderly, according to the WHO. European Center for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA).
The World Health Organization said in May that new formulations should aim to produce antibody responses to XBB.1.5 or XBB.1.16 variants, adding that other formulations or platforms that achieve neutralizing antibody responses against XBB strains could also be considered.
[ad_2]
